(Q24320715)

2

0 references

Xi-Dai Long

3

0 references

Wei Wang

4

0 references

Hui-Ke Jiao

5

0 references

Zhu Mei

6

0 references

Qian-Qian Yin

7

0 references

Li-Na Ma

8

0 references

Ai-Wu Zhou

9

0 references

Li-Shun Wang

10

0 references

Ming Yao

11

0 references

Qiang Xia

12

0 references

Guo-Qiang Chen

Hypoxia-Inducible Factors: Post-translational Crosstalk of Signaling Pathways

13

0 references

language of work or name

English

0 references

publication date

13 January 2014

0 references

published in

Cancer Cell

0 references

volume

25

0 references

issue

1

0 references

page(s)

118-31

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

VEGF is essential for the growth and migration of human hepatocellular carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

The role and clinical implications of microRNAs in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Metabolic alteration in tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Sumoylation increases HIF-1alpha stability and its transcriptional activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

SUMOylation of hypoxia-inducible factor-1alpha reduces its transcriptional activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Tumor cell dissemination: emerging biological insights from animal models and cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Hypoxia-inducible factors in physiology and medicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Biochemical mechanisms of gene regulation by polycomb group protein complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Intracellular signaling and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Regulation of human epidermal stem cell proliferation and senescence requires polycomb- dependent and -independent functions of Cbx4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Polycomb group protein-mediated repression of transcription

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Passing the baton: the HIF switch

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Polycombing the genome: PcG, trxG, and chromatin silencing

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

The polycomb protein Pc2 is a SUMO E3

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Molecular features of human ubiquitin-like SUMO genes and their encoded proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Regulation of angiogenesis by hypoxia: role of the HIF system

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Tumor angiogenesis: molecular pathways and therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Pathological neoangiogenesis depends on oxidative stress regulation by ATM.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Hypoxia--a key regulatory factor in tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Adverse effects of anticancer agents that target the VEGF pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

HCC and angiogenesis: possible targets and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Polycomb silencing mechanisms and the management of genomic programmes

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

PIASy stimulates HIF1α SUMOylation and negatively regulates HIF1α activity in response to hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Polycomb protein Cbx4 promotes SUMO modification of de novo DNA methyltransferase Dnmt3a

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

1 reference

7 January 2021

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Hypoxia: A Link between Fibrogenesis, Angiogenesis, and Carcinogenesis in Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Pc2-mediated sumoylation of Smad-interacting protein 1 attenuates transcriptional repression of E-cadherin

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Role of polycomb group proteins in stem cell self-renewal and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Polycomb proteins in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

SUMO-dependent regulation of centrin-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

A role for non-covalent SUMO interaction motifs in Pc2/CBX4 E3 activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Deciphering the emerging role of SUMO conjugation in the hypoxia-signaling cascade

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Current advances in tumor proteomics and candidate biomarkers for hepatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.12.008

7 January 2021

Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab

1 reference